  The US Pharmacopeia (Rockville, MD, USP, 

) recently announced that the  implementation period for its 

 general notices statement requiring all manufacturers to conform to recently  revised residual solvent standards in General Chapter <467> has been  extended from July 1, 2007 to July 1, 2008.

 requirements are designed to ensure consistency from one manufacturer to  another in several areas: testing for residual solvents, procedures for the  test, acceptance criteria and, when needed, reference materials. 

Residual solvents are one of three main types of impurities  in pharmaceutical products (the other two are organic and inorganic impurities).  All products affected by the extension still remain subject to FDA control. The  USP residual solvents standards only affect drug products and ingredients with  monographs in 

Compendial Compliance

Manufacturing

Manufacturing, Aseptic Processing

News

Quality Control/Quality Assurance

Quality/GMPs

Regulatory/GMP Compliance

The US Pharmacopeia (Rockville, MD, USP, www.usp.org) recently announced that the implementation period for its USP­–NF general notices statement requiring all manufacturers to conform to recently revised residual solvent standards in General Chapter <467> has been extended from July 1, 2007 to July 1, 2008.